Brief: Jaypirca® (Pirtobrutinib) Approved In China For A New Indication In Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines Of Therapy
28/09/2026 11:39
BRIEF-Jaypirca® (Pirtobrutinib) Approved In China For A New Indication In Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines Of Therapy Sept 28 (Reuters) - Innovent Biologics, Inc. 1801.HK:
JAYPIRCA® (PIRTOBRUTINIB) APPROVED IN CHINA FOR A NEW INDICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) /SMALL LYMPHOCYTIC LYMPHOMA (SLL) ACROSS ALL LINES OF THERAPY
Source text: ID:nPn8Nn4xSa
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis